Enovis Corporation
| NYSE: ENOV |
| Industrials / Industrial Products / USA |
| 56.00 | +1.00 | +1.82% | Vol 393.69K | 1Y Perf -115.38% |
| Jul 1st, 2022 16:00 DELAYED |
| BID | 54.00 | ASK | 57.99 | ||
| Open | 54.93 | Previous Close | 56.00 | ||
| Pre-Market | - | After-Market | 56.00 | ||
| - - | - -% |
| Target Price | 126.84 | Analyst Rating | Hold 2.60 | |
| Potential % | 126.50 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 43.26 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 46.19 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.38 | Earnings Rating | — | |
| Market Cap | 3.03B | Earnings Date | 27th Jul 2022 | |
| Alpha | -0.04 | Standard Deviation | 0.17 | |
| Beta | 2.67 |
Today's Price Range 54.4956.41 | 52W Range 54.3372.13 | 5 Year PE Ratio Range -1.80101.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.88% | ||
| 1 Month | -16.94% | ||
| 3 Months | -118.00% | ||
| 6 Months | -115.89% | ||
| 1 Year | -115.38% | ||
| 3 Years | -127.02% | ||
| 5 Years | -118.56% | ||
| 10 Years | -126.22% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2.36 | |||
ROE last 12 Months | 1.57 | |||
ROA (5Y Avg) | -1.00 | |||
ROA last 12 Months | 0.84 | |||
ROC (5Y Avg) | 0.35 | |||
ROC last 12 Months | 1.56 | |||
Return on invested Capital Q | 0.35 | |||
Return on invested Capital Y | 0.14 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 7.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 47.00 | ||||
| 0.68 | ||||
| 0.80 | ||||
| 12.10 | ||||
| 158.30 | ||||
| 4.80 | ||||
| -6.59 | ||||
| 85.14 | ||||
| 4.74B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 1.60 | ||||
| 0.28 | ||||
| 0.49 | ||||
| 3.70 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.80 | ||||
| 5.70 | ||||
| 12.40 | ||||
| 2.40 | ||||
| 1.80 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.00B | ||||
| 74.00 | ||||
| 0.44 | ||||
| 0.30 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | 0.34 | 0.37 | 8.82 |
| Q04 2021 | 1.71 | 1.77 | 3.51 |
| Q03 2021 | 1.62 | 1.62 | 0.00 |
| Q02 2021 | 1.59 | 1.68 | 5.66 |
| Q01 2021 | 1.17 | 1.32 | 12.82 |
| Q04 2020 | 1.47 | 1.53 | 4.08 |
| Q03 2020 | 0.40 | 0.41 | 2.50 |
| Q02 2020 | 0.06 | 0.09 | 50.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 27th Jul 2022 |
| Estimated EPS Next Report | 0.49 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 393.69K |
| Shares Outstanding | 54.03K |
| Shares Float | 44.35M |
| Trades Count | 7.95K |
| Dollar Volume | 21.83M |
| Avg. Volume | 508.59K |
| Avg. Weekly Volume | 475.86K |
| Avg. Monthly Volume | 427.94K |
| Avg. Quarterly Volume | 621.96K |
Enovis Corporation (NYSE: ENOV) stock closed at 56 per share at the end of the most recent trading day (a 1.82% change compared to the prior day closing price) with a volume of 393.69K shares and market capitalization of 3.03B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Industrial Products industry, Industrials sector and employs 16200 people. Enovis Corporation CEO is Matthew L. Trerotola.
The one-year performance of Enovis Corporation stock is -115.38%, while year-to-date (YTD) performance is -115.89%. ENOV stock has a five-year performance of -118.56%. Its 52-week range is between 54.33 and 72.13, which gives ENOV stock a 52-week price range ratio of 9.38%
Enovis Corporation currently has a PE ratio of 47.00, a price-to-book (PB) ratio of 0.68, a price-to-sale (PS) ratio of 0.80, a price to cashflow ratio of 12.10, a PEG ratio of 2.32, a ROA of 0.84%, a ROC of 1.56% and a ROE of 1.57%. The company’s profit margin is 1.80%, its EBITDA margin is 12.40%, and its revenue ttm is $4.00 Billion , which makes it $74.00 revenue per share.
Of the last four earnings reports from Enovis Corporation, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.49 for the next earnings report. Enovis Corporation’s next earnings report date is 27th Jul 2022.
The consensus rating of Wall Street analysts for Enovis Corporation is Hold (2.6), with a target price of $126.84, which is +126.50% compared to the current price. The earnings rating for Enovis Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enovis Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enovis Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 36.94, ATR14 : 2.68, CCI20 : -77.15, Chaikin Money Flow : -0.18, MACD : 1.95, Money Flow Index : 34.82, ROC : -7.15, RSI : 60.13, STOCH (14,3) : 21.27, STOCH RSI : 0.18, UO : 48.03, Williams %R : -78.73), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enovis Corporation in the last 12-months were:
Enovis Corporation
Colfax is a diversified technology firm that produces welding equipment and medical devices. Following the sale of its air and gas handling business in 2019, Colfax's remaining portfolio is organized into two segments: fabrication technology and medical technology. Fabrication technology is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications, mostly marketed under the ESAB brand name. The medical technology segment makes medical devices, including orthopedic braces, reconstructive implants, and other products used for rehabilitation, physical therapy, and pain management. The company generated roughly $3.9 billion in revenue in 2021.
CEO: Matthew L. Trerotola
Telephone: +1 302 252-9160
Address: 420 National Business Parkway, Annapolis Junction 20701, MD, US
Number of employees: 16 200
